Breast preserving surgery decision making

Anticancer Research

Volumn 18, Issue 3 C, 1998, Pages 2107-2137

  Schauer, A ^a   Marx, D ^a   Schauer, M ^a   Binder, C ^a   Kuhn, W ^a   Meden, H ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Angiogenesis; Atypical ductal hyperplasia (ADH); Breast cancer; c erbB1; c erbB2; c erbB3; Ductal carcinoma in situ (DCIS); Extensive intraductal component (EIC); Lobular carcinoma in situ (LCIS); Metastasis; Oncogenes; p53; Prognostic factors; Proteases; Vimentin

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; VIMENTIN;

ANGIOGENESIS; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER RECURRENCE; CELL PROLIFERATION; CYSTOSARCOMA PHYLLOIDES; EPITHELIUM CELL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL DECISION MAKING; MESENCHYME; METASTASIS; ONCOGENE C ERB; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; DECISION MAKING; FEMALE; HUMANS; SURGICAL PROCEDURES, OPERATIVE;

EID: 0031880459     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Heywang-Köbrunner SH, Viehweg P, Heinig A, Kucheer C: Contrast enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol 24: 94-108 ,1997.
2. Barth V: Diagnosis of breast carcinoma: "Mammography and additive methods." Zentralbl Gynäkol 112: 1281-1269, 1990.
3. Fischer U, Westerhof JP, Brinck U, Korabiowska M, Schauer A, Grabbe E: Ductal carcinoma in situ in dynamic MR-mammography at 1,5 T. RöFo Geb Röntgenstr Neuen Bildgeb Verfahr 164: 290-294, 1996.
4. Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E: Prognostic value of contrast-enhanced MR-mammography in patients with breast cancer. Eur Radiol 7: 1002-1005, 1997.
5. Mumtaz H, Hall-Craggs MA, Davidson T, Walmsley K, Thurell W, Kissin MW, Tayler I: Staging of symptomatic primary breast cancer with MR imaging. Am J Roentgenol 169: 417-424, 1997.
6. Lanyi M, Stiens R, Stilletto M: Intraductale Anteile und Mikroinvasionsherde beim ductalen Mammacarcinom im Mammogramm. Fortschritte Röntgenstr 161: 195-200, 1994.
7. Schreer I and Heywang-Köbrunner SH: Early detection of breast cancer. Gynaekologe 27: 12-16, 1994.
8. Neitzel U, Maack I, Gunther-Kohfahl S: Image quality of a digital chest radiography system based on a selenium detector. Med Phys 21: 509-516, 1994.
9. Heywang-Köbrunner SH, Beck R: Contrast enhanced MRI of the breast. Springer Berlin 74-82, 1995.
10. Grosse A, Schreer I, Frischbier HJ, Maass H, Loening T, Bahnsen J: Results of breast conserving therapy for early breast cancer and the role of mammographic follow up. Int J Radiat Oncol Biol Phys 38: 761-767, 1997.
11. Orel SG, Mendonca MH, Reynolds C, Schnall MD, Solin LJ, Sullivan DC: MR imaging of ductal carcinoma in situ. Radiology 202: 413-420, 1997.
12. Schulz-Wendtland R, Kramer S, Doinghaus-Mitze M, Lang N: Interventional techniques in breast diagnosis: ultrasound controlled puncture biopsy. Aktuelle Radiology 7: 30-34, 1997.
13. Schauer A: Pathologische Anatomie des Mammacarcinoms. In: R Siewert, A Schauer, G Nagel und R Frischkorn (eds.): Mammacarcinom. Chirurgie der Gegenwart Urban und Schwarzenberg (München) 6-39, 1981.
14. Schauer A: Pathologische Anatomie des Mammacarcinoms. In: FW Schildberg und E Kiffner (eds.): Interdisziplinäre Therapie des Mammacarcinoms. Perimed Verlag Erlangen, 1984.
15. Pijnappel RM, van Dalen A, Rinkes IH, van den Tweel JG, Mali WP: The diagnostic accuracy of core biopsy in palpable and nonpalpabel breast lesions. Eur J Radiol 24: 120-123, 1997.
16. Marchall LM, Hunter DJ, Conolly JL, Schmitt SJ, Byrne C, London SJ, Colditz GA: Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemial Biomarkers-Prev 6: 297-301, 1997.
17. Jackman RJ, Burbank F, Parker SH, Evans WP, Lechner MC, Richardson TR, Tocino I, Wrang AB: Atypical ductal hyperplasia diagnosed at stereotactic biopsy: improved reliability with 14 gauge, directional vacuum-assisted biopsy. Radiology 204: 485-488, 1997.
18. Burbank F: Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: unproved accuracy with directional vaccuum-assisted biopsy. Radiology 202: 843-847, 1997.
19. Moore MM, Hargett CW 3rd, Hanks JB, Fajardo LL, Harvey JA, Frierson HF Jr, Slingluff CL Jr: Association of breast cancer with the finding of atypical ductal hyperplasia at core breast biopsy. Ann Surg 225: 726-731, 1997.
20. Bergholz M, Schauer A, Reck H: Krebsrisiko bei papillären Proliferationen der Brustdrüse. Langenbecks Arch Chir 348: 157-165, 1979.
21. Lagios MD, Westdahl PR, Margolin FR, Rose MR: Duct carcinoma in situ. Relationship of extent of non invasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short term treatment failures. Cancer 50: 1309-1314, 1982.
22. Silverstein MJ, Graig PH, Lagios MD, Waisman JK, Levinsky BS, Colburn WJ, Poller DN: Developing a prognostic index for ductal carcinoma in situ of the breast are we there yet? Cancer 78: 1138-1140, 1996.
23. Silverstein MJ, Lagios MD: Use of predictors of recurrence to plan therapy for DCIS of the breast. Oncology-Huntingt 11(3): 393-406, 409-410, 413-415, 1997.
24. Posner MC and Wolmark N: Non invasive breast cancer. Breast Cancer Res Treat 21: 155-164, 1992.
25. Abrams JS, Phillips PH, Friedman MA: Meeting high lights: a reappraisal of research results for the local treatment of early stage breast cancer. J Nat Cancer Inst 87: 1837-1845, 1995.
26. Baldetorp B, Fernö M, Fallenius A, Fallenius-Vecchi G, Idvall I, Olsson H, Sigurdsson B, Åkerman M and Killander D: Image Cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry 13: 577-585, 1992.
27. Webber BL, Heise H, Neifeld YP, Costa J: Risk of subsequent contralateral breast carcinoma in a population of patients with in situ breast carcinoma. Cancer 47: 2928-2932, 1981.
28. Sauer R, Rauschecker HF, Schauer A, Schumacher M, Dunst J: Therapy of early breast cancer: Preliminary results of the German Breast cancer Study. Recent Results in Cancer Res 15: 203-210, 1989.
29. Sauer R, Schauer A, Rauschecker HF, Schumacher M, Gatzemeier W, Schmoor C, Dunst J, Seegenschmiedt MH, Marx D: Therapy of small breast cancer: A prospective study on 1036 patients with special emphasis on prognostic factors. Int J Radiation Oncology Biol Phys 23: 907-914, 1992.
30. Sauer R, Strnad V, Schauer A, Rauschecker HF, Schumacher M: Saving the breast versus mastectomy in the small breast cancer. Results of the GBSG (German Breast Cancer Study Group. Gynaec.Geburtshilfe Rundsch. 33 Suppl. 1: 93-94, 1993.
31. Schauer A: Die Multicenter Studie "Kleines Mammacarcinom". Supported by the Ministry for Research and Technology. Deutsches Ärzteblatt 87: 2559-2564, 1990.
32. Schauer A, Marx D, Ummenhofer L, Rauschecker H, Gatzemeier W, Sauer R, Schumacher M, Sauerbrei W: Die Multicenter Studie "Kleines Mammacarcinom. Vorläufige Ergebnisse - Neue Aspekte." Dt. Ärzteblatt87: 3628-38, 1990.
33. 0-Fällen des Mammacarcinoms. Bezug zur locoregionären Recidivbildung und hämatogener Tumor-progression. Verb Dt Ges f Path 75: 239, 1991.
34. Schauer A, Marx D, Lipp I, Meden H, Schumacher M, Sauerbrei W, Rauschecker H: Clinical and Scientific aspects of HER-2/Neu c-erbB2 oncogene. Biological relevance of c-erbB2-oncogene in malignant epithelial tumors. In: Jonat W, Löning R (eds.): Clinical and Scientific aspects of HER-2/neu erbB2 Int Symp Hamburg AGO Oncology 1991.
35. Schauer A, Marx D, Lipp I, Schumacher M, Sauerbrei W, Rauscheker H, Sauer R: Diagnostic tools and prognostic factors in human breast cancer evaluated by morphological and immunohistochemical methods. In: Dogliotti L, Sapino A, Bussolati G (eds.): Breast cancer: Biological and clinical progress. Kluwer Academical Publishers (Dordrecht) 255: 176, 1992.
36. Rauschecker HF, Gatzemeier W, Sauer R, Seegenschmiedt MH, Schauer A, Ummenhofer L, Sauerbrei W, Schmoor C, Schumacher M: Initial results of the project of the German Breast Cancer Study Group on Breast Saving Therapy of the small breast cancer. Chirurg 63: 495-500, 1992.
37. Rauschecker H, Sauer R, Schauer A, Schumacher M: Study I Therapy of small breast cancer. Four years results of a prospective non randomized study. Kluwer, 1994.
38. Schauer A, Weiß A: Bedeutung des Tumorgrading und der Blutgefäßeinbrüche für die Verlaufsbeurteilung des Mammacarcinoms bei Stadium I-Patientinnen. Verh Dt Ges Path 65: 382, 1981.
39. Fisher E: personal communication, 1986.
40. Holland R, Connolly JL, Gelman R, Mravunak M, Hendrics JH, Verbeek AL, Schmitt SJ, Silver B, Boyages J, Harris JR: The presence of an extensive intraductal component following a limited exscision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 8: 113-118, 1990.
41. Fisher B, Bauer M, Margolese R, Poisson R, Pilch Y, Redmond R, Fisher E, Wolmark N, Deutsch M, Montgue E: Five years results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. New Engl J Med 312: 665-673, 1985.
42. Fisher B, Redmond C, Poisson R, Margolese R, Wolmark N, Wickerham L, Fisher E, Deutsch M, Caplan R, Pilch Y: Eight Year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. New Engl J Med 320: 822-828, 1989.
43. Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, Mamounas EP, Deutsch M, Margolese R: Significance of ipsilateral breast tumor recurrence after lumpectomy. Lancet 338: 327-331, 1991.
44. Fisher B and Anderson S: Conservative surgery for the management of invasive and noninvasive carcinoma of the breast NSABP-Trials. National Surgical Adjuvant Breast and Bowel Project. World J Surg 18: 63-69, 1994.
45. Kurtz JM, Amalric R, Brandone H, Ayme Y, Jacquemier J, Pietra JC, Hans D, Pollet JF, Bressac C, Spitalier JM: Local recurrence after breast conserving surgery and radiotherapy. Frequency, time course and prognosis. Cancer 63: 1912-1917, 1989.
46. Auer GU, Caspersson TO, Wallgren AS: DNA content and survival in mammary carcinoma. Analyt Quant Cytol 2: 161-165, 1980.
47. Clark GN, Dressier LG, Owens MA, Pounds G, Oldaker T and McGuire WL: Prediction of relapse or survival in patients with node negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633, 1989.
48. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T and Merkel D: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14: 482-485, 1993.
49. Bloom HJG and Richardson WW: Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.
50. Adams S, Harms H, Aus HM, Schauer A: Photometrische Steroidrezeptoranalyse des Mammacarcinoms. Verh Dt Ges f Path 72: 391, 1998.
51. Harms H, Aus HM, Schauer A, Brehler R: Neue photometrische Bestimmungsmöglichkeiten der immunhistochemischen Rezeptoranalyse. Enke Verlag Stuttgart (Bücherei des Frauenarztes) 28-31, 1989.
52. Tandon AK, Clark GM, Chamness GC: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Invest 7: 1120-1128, 1989.
53. Marx D, Schauer A, Reiche C, May A, Ummenhofer L, Reles A, Rauschecker HF, Sauer R, Schumacher M: c-erbB2-expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116: 15-20, 1990.
54. Marx D, Schauer A: Expression of the c-erbB oncoproteins in breast cancer. J Cancer Res Clin Oncol 120 (suppl.): R3, 1994.
55. Gullick WJ: The role of the epidermal growth factor receptor and the c-erbB2 protein in breast cancer. Int J Cancer Suppl 5: 55-61, 1990.
56. Wright C, Angus B, Nicholson S: Expression of c-erbB2-oncoprotein: A prognostic indicator in human breast. Cancer Res 49: 2087-2090, 1989.
57. Allred DC, Clark GM, Elledge R: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node negative breast cancer. J Nat Cancer Inst 85: 200-206, 1993.
58. Allred DC, Clark GM, Molina R: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23: 974-979, 1992.
59. Borg A, Baldetorp B, Fernö M, Killander D, Olsson H and Sigurdsson H: ErbB2 amplification in breast cancer with high rate of proliferation. Oncogene 6: 137-143, 1991.
60. Seegenschmiedt MH, Sauerbrei W, Sauer R, Schumacher M, Schauer A, Rauschecker HF, Dinkloh H, Dühmke E, Haase KD, Haase W et al: Quality control review for radiotherapy of small breast cancer. Analysis of 708 Patients in the GBSG I-Trial. Strahlenther Oncol 169: 339-350, 1993.
61. Imyanitov EN, Chernitsa OI, Serova OM, Nikoforova IF, Pluzhnikova GF, Knyazev PG: Amplification of HER-2 (erbB2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Neoplasma 40: 35-39, 1993.
62. Knyazev PG, Imyanitov EN, Chernitsa OI, Nikiforova IF: Loss of heterozygosity at chromosome 17p is associated with HER-2 amplification and lack of nodal involvement in breast cancer. Int J Cancer 53: 11-16, 1993.
63. DePotter CR, Schelfhout AM, Verbeeck P, Lakhani SR, Brunken R, Schroeter CA, Van den Tweel JG, Schauer AJ, Sloane JP: New overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. Human Pathology 26: 601-606, 1995.
64. Cattoretti G, Rilke F, Andreola S: p53 expression in breast cancer. Int J Cancer 41: 178-183, 1988.
65. Davidoff AM, Herndon JE, 2d Glover NS, Kerns BJ, Pence JC, Iglehart JD, Marks JR: Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 110: 259-264, 1991.
66. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR: Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci 88: 5006-5010, 1991.
67. Davidoff AM, Kerns BJ, Iglehart JD, Marks JR: Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51: 2605, 1991.
68. Davidoff AM, Kerns BJ, Pence JC, Marks JR, Iglehart JD: p53 alterations in all stages of breast cancer. J Surg Oncol 48: 260-267, 1991.
69. Horak E, Smith K, Bromley L, LeJeune S, Greenall M, Lane D, Harris AL: Mutant p53, EGF-Receptor and c-erbB2-expression in human breast cancer. Oncogene 6: 2277-2284, 1991.
70. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82: 835-840, 1991.
71. Hollstein M, Sidransky D, Vogelstein B: p53 mutations in human cancers. Science 253: 49-53, 1991.
72. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD: p53 and C-erbB2-protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status proliferation markers and clinical stage in human breast cancer. Am J Clin Pathol 98: 408-418, 1992.
73. Barbareschi M, Pelosio P, Caffo O, Buttitta F, Pellegrini S, Barbazza R, Dalla-Palma P, Bevilacqua G, Marchetti A: Cyclin D1 gene amplification and expression in breast carcinoma: relation with clinico pathologic characteristics and with retinoblastom gene product, p53 and p21 WAF1 immunohistochemical expression. Int J Cancer 74: 171-174, 1997.
74. Raillo M, Lundin J, Haglund C, von Smitten K, von Boguslawsky K, Nordling S: Ki67, p53, Er-Receptors ploidy and S-phase as prognostic factors in T1 negative breast cancer. Acta Oncol 36: 369-374, 1997.
75. Kesari AL, Chellam VG, Nair PP, Ahmed I, Madhavan J, Thomas PA, Nair MK, Pillai MR: p53-tumor suppressor protein and tissue proliferative fraction in infiltrating duct carcinoma. J Surg Oncol 65: 159-163, 1997.
76. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, Chambers AF: Osteopontin and p53 expression are associated with tumorprogression in a case of synchronous bilateral invasive mammary carcinoma. Arch Pathol Lab Med 121: 578-584, 1997.
77. Helal T, Nassiri M, Khalifa A: Immunohistochemical markers of tumorprognosis in breast cancer in Egypt. Cancer Detect Prev 21: 201-206, 1997.
78. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK: BC12, p53 and response to tamoxifen in estrogen receptor positive metastatic breast cancer: A South-west oncology group study. J Clin Oncol 15: 1916-22, 1997.
79. Thomas MD, McIntosh GG, Anderson JJ, McKenna DM, Parr AH, Johnstone R, Lennard TW, Horne CH, Angus B: A novel quatitative immunoassay system for p53 using antibodies selected for optimum designation of p53 status. J Clin Pathol 50: 143-147, 1997.
80. Rajan PB, Scott DJ, Perry RH, Griffith CD: p53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res Treat 42: 283-290, 1997.
81. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, Lennard TJ, Angus B, Home CH: p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164: 75-81, 1991.
82. Sawan A, Randall B, Angus B, Wright C, Henry JA, Ostrowski Y, Hennessy C, Lennard TW, Corbett I, Home CH: Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 168: 23-28, 1992.
83. Witte F, Hönig A, Mirecka J, Marx D, Schauer A: Cystosarcoma phylloides der Mamma, prognostische Relevanz der proliferation-saktivität und Apoptose tegulierender Gene. Verh Dtsch Ges Path 81: 536, 1997.
84. 2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables. Annals of Oncol 6: 1005-1010, 1995.
85. Schauer A, Binder C, Marx D, Kaiser HE: Tumor regression in breast cancer-spontaneous and induced. Anticancer Res 15: 1788, 1995.
86. Harris and Horak: Angiogenesis: Vascularization by tumor type, grade and lymph node, (LN) Status. Recent Results in Cancer Research 1993.
87. Rochefort H, Capony F, Garcia M, Cavalles VM, Freiss G, Chambon M, Morisset M, Vignon F: Estrogen induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J Cell Biochem 35: 17-29, 1987.
88. Thorpe SM, Rochefort H, Carcia M, Freiss G, Christensen IJ, Khalaf S, Paolucci F, Pau B, Bruun Rasmussen B, Rose C: Association between high concentrations of M 52000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res 49: 6008-6014.
89. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F, Graeff H: Time varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1 and steroid hormon receptor status in primary breast cancer. Br J Cancer 76: 306-311, 1997.
90. Domagala W, Lasota Y, Dukowicz A, Markiewski M, Striker G, Weber K and Osborn M: Vimentin expression seems to be associated with poor prognosis in node negative ductal NOS-breast carcinoma. Am J Pathol 137: 1299-1304, 1990.
91. Obermeyer N, Schauer A: unpublished data
92. Schlimok G, Riethmüller G: Detection, Characterization and tumorigenicity of disseminated tumor cells in human bone marrow. Semin Lancer Biol 1: 207-215, 1990.
93. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G: Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 10: 1534-1539, 1992.
94. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G: Monoclonal antibodies to detect breast cancer cells in bone marrow. Important Adv Oncol, 143-164, 1994.
95. Robbins P, Pinder S, deKlerk N, Dawkins H, Harvey J, Sterrett S, Ellis I and Elston C: Histological grading of breast carcinoma - a study of interobserver agreement. Human Pathol 26: 873-879, 1995.
96. Schauer A, Rothe H, Balzer I, Bergholz M et al: Monoclonal antibodies for improved evaluation of breast cancer prognosis. In: MA Rich, JC Hager, DM Lopez (eds.): Breast Cancer: Scientific and Clinical Progress. Kluwer, Boston 299-320, 1988.
97. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.